oliceridine

October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500's 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA...

Trevena Inc (NASDAQ: TRVN) has a key catalyst Oct. 11, when the FDA's Anesthetic and Analgesic Drug Products Advisory Committee is scheduled to announce its verdict on the safety, efficacy and benefit considerations for the company's pain medication candidate Oliceridine. Ahead of the D-...

Trevena Inc (NASDAQ: TRVN), a clinical-stage biopharmaceutical company that focuses on therapeutics that use an approach to target G protein coupled receptors (GPCRs), saw its shares plummet around 30 percent Tuesday morning despite a positive development in Phase 3 trials. Trevena announced...